Article
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.
Clinical lung cancer - 1 Jul 2021
Lu Shun, Casarini Ignacio, Kato Terufumi, Cobo Manuel, Özgüroğlu Mustafa, Hodge Rachel, van der Gronde Toon, Saggese Matilde, Ramalingam Suresh S
Abstract excerpt
The LAURA trial (NCT03521154) will evaluate the efficacy and safety of osimertinib as maintenance therapy in patients with locally advanced, unresectable, epidermal growth factor receptor mutation-positive (EGFRm), stage III non-small-cell lung cancer (NSCLC) without disease progression during/following definitive platinum-based chemoradiation therapy (CRT). Eligible patients include adults aged ≥ 18 years (≥ 20...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.